A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants

• Danicopan (Drug), also known as ALXN2040, ACH-0144471 (formerly): Oral tablet.
• Midazolam (Drug), also known as Midazolam HCl: Oral syrup.
• Fexofenadine (Drug): Oral tablet.
• Mycophenolate Mofetil (Drug): Oral tablet.

Primary outcomes

• Part 1: Midazolam Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Observed Non-zero Concentration (AUC0-t) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan [Up to 24 hours postdose]
• Part 1: Midazolam Area Under The Plasma Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan [Up to 24 hours postdose]
• Part 1: Midazolam Maximum Observed Plasma Concentration (Cmax) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan [Up to 24 hours postdose]
• Part 1: Midazolam Time To Reach Maximum Observed Plasma Concentration (Tmax) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan [Up to 24 hours postdose]
• Part 2: Fexofenadine AUC0-t Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 2: Fexofenadine AUC0-inf Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 2: Fexofenadine Cmax Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 2: Fexofenadine Tmax Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 3: Mycophenolic Acid (MPA) and Mycophenolic Acid Glucuronide (MPAG) AUC0-t Following Single-dose Mycophenolate Mofetil (MMF) Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 3: MPA and MPAG AUC0-inf Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 3: MPA and MPAG Cmax Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]
• Part 3: MPA and MPAG Tmax Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan [Up to 72 hours postdose]

Secondary outcomes

• Parts 1-3: Participants Experiencing Treatment-emergent Adverse Events [7 (±1) days following the last dose in Period 2]

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Key Inclusion Criteria:

* Healthy was defined as having no clinically relevant abnormalities identified by a detailed medical history, physical examination, blood pressure and heart rate measurements, 12-lead electrocardiogram, and clinical laboratory tests.
* Body mass index of 18.5 to 32 kilograms (kg)/square meter with a minimum body weight of 50 kg.

Key Exclusion Criteria:

* Mentally or legally incapacitated or significant emotional problems.
* Any condition that might interfere with drug absorption.
* History of sensitivity to study medication or other drug allergies.
* Body temperature greater than or equal to 38°Celsius on Day -1 or Day 1 predose; history of febrile illness within 14 days of the first dose.
* Positive urine drug test; current tobacco/nicotine users and smokers; consumption of alcohol within 72 hours of study drug administration.
* Participated in another clinical study within 28 days prior to the first dose.
* Significant laboratory abnormalities.
* Blood donation of more than 500 milliliters within 3 months of the first dose; received a blood transfusion or blood products within 6 months to the first dose.